Clinical Trial Update: Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC [Phase 1, Phase 2]

View source ↗

Summary

ClinicalTrials.gov update describes a Phase 1/2 study evaluating autologous immune cell therapy in combination with a luteinizing hormone-releasing hormone agon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Autologous Immune Cell Therapy
• Luteinizing hormone-releasing hormone agonist (LHRH agonist)

Snippet

Sponsor: Shanghai AbelZeta Ltd. | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: UNKNOWN